Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2022/06/043467
CTRI/2022/06/043467
Not yet recruiting
Phase 4

Prospective, observational study in Sickle Cell Diseasepatients on crizanlizumab treatment in Middle Eastcountries and India (SPOTLIGHT)

ovartis Healthcare Pvt Ltd0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
ovartis Healthcare Pvt Ltd
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational

Investigators

Sponsor
ovartis Healthcare Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • •1\. Male and female patients with clinical diagnosis of SCD (based on laboratory parameters)
  • •of any genotype.
  • •2\. Patients newly initiated on treatment with locally approved crizanlizumab.
  • •3\. Patients aged 16 years or older at crizanlizumab initiation.

Exclusion Criteria

  • •1\. Patients who did not provide informed consent.
  • •2\. Patients who received a stem cell transplant at the time of enrollment.
  • •3\. Patients who participated in or participating in a clinical trial at the time of enrollment or
  • •in the 12 months prior to starting commercial crizanlizumab.
  • •4\. According to the investigatorâ??s opinion, the patient is an unlikely candidate to provide an
  • •accurate medical history and/or to obtain long\-term follow\-up information for any reasons
  • •such as unavailability or severe concomitant illnesses.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 3
Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector
2024-513901-30-00Bluebird Bio Inc.3
Recruiting
Phase 1
ong-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector
CTIS2024-513901-30-00Bluebird Bio Inc.88
Terminated
Not Applicable
Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and IndiaSickle Cell Disease
NCT05020873Novartis Pharmaceuticals44
Recruiting
Not Applicable
Sickle Cell Outcome Research
NL-OMON29491A1,000
Recruiting
Not Applicable
Sickle Cell Outcome REsearch
NL-OMON55241Erasmus MC, Universitair Medisch Centrum Rotterdam1,000